Cyflumetofen
Based on 1 Customer Validation
Cyflumetofen is a non-systemic acylacetonitrile Acaricide. Cyflumetofen interferes with the Wnt/β-catenin signaling pathway, induces Apoptosis, and reduces the level of tight junction proteins. Cyflumetofen upregulates the expression of Pink1, Parkin and Lrrk2 genes associated with the pathogenesis of Parkinson's disease in zebrafish larvae. Cyflumetofen induces developmental toxicity and oxidative stress in zebrafish larvae, damages neurons, reduces motor activity, alters brain tissue structure, and disrupts blood-brain barrier structure. Cyflumetofen exhibits acaricidal activity against spider mites. Cyflumetofen can be used in studies related to Parkinson's disease and infestations by spider mites (Tetranychus urticae, Tetranychus kanzawai, Panonychus citri).
For research use only. We do not sell to patients.
- Purity: 98.94%
- CAS No.: 400882-07-7
- Formula: C24H24F3NO4
- Molecular Weight:447.45
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Parasite Isoforms
More
Biological Activity
Cyflumetofen potently inhibits Tetranychus urticae mitochondrial complex II with an IC50 of 31.2 nM[2].
Cyflumetofen (100 µM; 1-12 h) is metabolized to AB-1 (HY-120409) in Tetranychus urticae (20% after 12 h), Panonychus citri (40% after 12 h), Spodoptera litura, and Apis mellifera, with Panonychus citri showing a faster and higher metabolism rate than Tetranychus urticae[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cyflumetofen (>2000 mg/kg; single dose) exhibits low acute toxicity in female BrlHan:WIST@Jcl rats, with an LD50 greater than 2000 mg/kg[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type AB; Tg(flk1:eGFP; gata1:mCherry); Tg(flk1:nucGFP); Tg(elavl3:eGFP); Tg(hb9:eGFP) (72 h post-fertilization larvae, exposed via culture medium to 144 h post-fertilization)[1]
-
Dosage:1.0 μg/mL; 2.0 μg/mL; 4.0 μg/mL; 8.0 μg/mL; 16.0 μg/mL
-
Administration:in culture medium; semi-static; 72 hours, fresh solution replaced daily
-
Result:Reduced zebrafish larvae survival rate to less than 25% at 16.0 μg/mL; maintained survival rate over 95% at ≤4.0 μg/mL.
Induced concentration-dependent developmental abnormalities including shortened body length, reduced heart rate, reduced swim bladder area, and increased yolk sac area/width at 1.0, 2.0, and 4.0 μg/mL.
Caused concentration-dependent decreases in fluorescence intensity of neuronal cells in the brain and spinal cord, and motor neurons in the spinal cord, with statistically significant reductions at all tested concentrations.
Reduced total movement distance, average swimming speed, and total movement time in a concentration-dependent manner; induced brain tissue damage with increased intercellular space and decreased cell density.
Increased acridine orange fluorescence in a concentration-dependent manner.
Increased DCFH2-DA fluorescence in a concentration-dependent manner; increased SOD and GSH activities; increased MDA content by 142% at 4.0 μg/mL.
Reduced fluorescence intensity of cerebral blood vessels, erythrocytes, and vascular endothelial cells; caused blood leakage in the central arteries region; reduced levels of tight junction proteins ZO-1, Claudin-5, and Occludin in a concentration-dependent manner.
Decreased protein levels of Wnt1, Wnt3a, and β-catenin; reduced mRNA expression of Wnt/β-catenin pathway genes *β-catenin*, *gsk3β*, and *axin2*; upregulated mRNA expression of Parkinson's disease-associated genes *pink1*, *parkin*, and *lrrk2* in a concentration-dependent manner.
-
Animal Model:BrlHan:WIST@Jcl (female)[2]
-
Dosage:>2000 mg/kg
-
Administration:single dose
-
Result:Showed no toxicity at the tested maximum dose.
Resulted in an LD50 value of >2000 mg/kg.
Chemical Information
-
CAS No. 400882-07-7
-
Appearance Solid
-
Molecular Weight 447.45
-
Formula C24H24F3NO4
-
Color White to off-white
-
SMILES
COCCOC(C(C(C1=C(C(F)(F)F)C=CC=C1)=O)(C2=CC=C(C(C)(C)C)C=C2)C#N)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (223.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang WG, et al. Cyflumetofen disrupts the blood-brain barrier and induces neurotoxicity in zebrafish larvae. Chemico-biological interactions. 2026 Mar 01;426:111911. [Content Brief]
[2]. Hayashi N, et al. Cyflumetofen, a novel acaricide - its mode of action and selectivity. Pest management science. 2013 Sep;69(9):1080-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2349 mL | 11.1744 mL | 22.3489 mL | 55.8722 mL |
| 5 mM | 0.4470 mL | 2.2349 mL | 4.4698 mL | 11.1744 mL | |
| 10 mM | 0.2235 mL | 1.1174 mL | 2.2349 mL | 5.5872 mL | |
| 15 mM | 0.1490 mL | 0.7450 mL | 1.4899 mL | 3.7248 mL | |
| 20 mM | 0.1117 mL | 0.5587 mL | 1.1174 mL | 2.7936 mL | |
| 25 mM | 0.0894 mL | 0.4470 mL | 0.8940 mL | 2.2349 mL | |
| 30 mM | 0.0745 mL | 0.3725 mL | 0.7450 mL | 1.8624 mL | |
| 40 mM | 0.0559 mL | 0.2794 mL | 0.5587 mL | 1.3968 mL | |
| 50 mM | 0.0447 mL | 0.2235 mL | 0.4470 mL | 1.1174 mL | |
| 60 mM | 0.0372 mL | 0.1862 mL | 0.3725 mL | 0.9312 mL | |
| 80 mM | 0.0279 mL | 0.1397 mL | 0.2794 mL | 0.6984 mL | |
| 100 mM | 0.0223 mL | 0.1117 mL | 0.2235 mL | 0.5587 mL |
Cyflumetofen Related Classifications
HY-W663938 Related Classifications
Powered by Bioz